Navigation Links
Unilife Corporation Announces Preliminary Financial Results for the Fourth Quarter and Fiscal Year 2011
Date:8/30/2011

ignment of our business to drive internal efficiencies, and signed an equipment financing agreement earlier this month for $10 million in available funding.

"Looking ahead, our Company has never been stronger or better positioned to capitalize on untapped opportunities within an injectable drug delivery device market forecast to increase by 50% to a total value of $15 billion in 2015.  I look forward to updating you as we continue to focus on serving the unmet needs of pharmaceutical companies through our uniquely designed innovation strategy, improving the lives of healthcare workers and patients across the globe, while building a stronger company that increases value for our stockholders," concluded Mr. Shortall.

Preliminary Financial Results for Three and Twelve Months Ended June 30, 2011 Revenues for the three months ended June 30, 2011 were $0.7 million compared to $2.7 million for the same period in 2010. This decrease was largely attributable to a decrease of $1.2 million in milestone payments from Unilife's pharmaceutical partner associated with the industrialization program for the Unifill syringe, as well as a decrease in product sales of $0.8 million reflecting the Company's decision to discontinue its contract manufacturing operations and instead focus on the commercialization, production and supply of its own propriety line of products.  

The Company's net loss for the three months ended June 30, 2011 was $(10.5) million, or $(0.17) per diluted share, compared to a net loss of $(9.7) million, or $(0.18) per diluted share, for the same period in 2010. The increase in the net loss was primarily attributable to the decrease in revenues as noted above, higher depreciation and amortization and increased research and development costs incurred to finalize the product specifications of our Unifill syringe. The increase in net loss was partially offset by decreased selling, general and administrative expenses due to a reducti
'/>"/>

SOURCE Unilife Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Unilife Develops Proprietary Range of Auto-Injectors for Patient Self-Administration of Injectable Drugs
2. Unilife Develops Unifill® EZMix Multiple-Chamber Prefilled Syringes
3. Unilife Signs $10 Million Equipment Financing Agreement
4. Unilife Expands Management Team to Support Business Growth
5. Unilife Starts Unifill Syringe Sales to Another Pharmaceutical Customer
6. Unilife Successfully Completes Industrialization of Unifill Syringe
7. Unilife Hosts White House Business Council Meeting
8. Unilife to Present at the 2011 Jefferies Global Healthcare Conference in New York City
9. Unilife to Present at the 2011 UBS Global Specialty Pharmaceuticals Conference in London
10. Unilife Announces Financial Results for the Third Quarter of Fiscal 2011
11. Unilife Corporation to Announce Financial Results for Fiscal 2011 Third Quarter on Monday, May 16, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... BOSTON , January 23, 2015 Heptares ... is delighted to announce that the Malcolm Campbell ... Congreve (Vice President of Chemistry), Fiona Marshall ... (Chief Executive Officer and co-founder) for the seminal contributions to ...
(Date:1/22/2015)... is pleased to announce the appointment of Dr. ... Biochemistry. Scott joins the company after previous scientific leadership positions ... course of his nearly 20 year career in therapeutics ... recognized thought leader in the biosensor field and particularly ...
(Date:1/22/2015)... , Jan. 22, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ... focus on Omega-3 therapies for cardiovascular disease and overall health ... Company,s accomplishments in 2014 and its outlook for 2015 from ... Fellow Shareholders, We would like to take this ...
Breaking Medicine Technology:Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7
... OrbusNeich announced that data from multiple clinical trials supporting ... cases where prolonged dual antiplatelet therapy (DAPT) is not ... "How to assess and treat patients who are not ... 2011 in Paris. Presenters discussed current treatment ...
... LAKE CITY, May 19, 2011 Paradigm Medical Industries, ... notification from its Italian partner, Costruzione Strumenti Oftalmici (CSO), ... pages and 24 attachments to the U.S. Food and ... for the Paramax™. This supportive information was submitted to ...
Cached Medicine Technology:OrbusNeich's Genous™ Stent is Safe and Effective in Cases Where Prolonged Dual Antiplatelet Therapy is Not Advisable as Presented at EuroPCR 2011 2OrbusNeich's Genous™ Stent is Safe and Effective in Cases Where Prolonged Dual Antiplatelet Therapy is Not Advisable as Presented at EuroPCR 2011 3OrbusNeich's Genous™ Stent is Safe and Effective in Cases Where Prolonged Dual Antiplatelet Therapy is Not Advisable as Presented at EuroPCR 2011 4Paramax™ Moves Closer To FDA Approval 2
(Date:1/22/2015)... 22, 2015 Joan Lunden, award-winning American ... at the upcoming 32nd Annual Miami Breast Cancer ... Education Resource®, LLC (PER®) , shares that “a fast-growing, ... undetected if she had not followed up her clean ...
(Date:1/22/2015)... Calif. (PRWEB) January 22, 2015 ... Susan Bonilla (D-Concord) and Kristin Olsen (R-Modesto) were ... their leadership in advancing biotechnology, biomedical science, medical ... and Olsen each received the “2014 Life Sciences ...
(Date:1/22/2015)... IsoComforter, Inc. has introduced the most innovative and ... to treat specific body parts and muscle groups. , ... to use patented cold therapy machine with the innovative IsoTube ... muscle injuries. IsoComforter has become the industry leader in ...
(Date:1/22/2015)... January 22, 2015 Payday lending practices ... communities and cause financial distress to the states that ... at Howard University’s Center on Race and Wealth. , ... economic activity, payday loans at the same time substantially ...
(Date:1/22/2015)... 2015 As interest in the value of ... momentum worldwide, Rev. Eric J. Hall , president and ... (HCCN), will be the keynote speaker on January 27 at ... health system. , The conference, “Hope and Resilience: Innovative and ...
Breaking Medicine News(10 mins):Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3
... exercise daily can improve mood and reduce fatigue, study reports. ... towars the physical asset. But as far as mental fatigue is ... benefit. This is based on the preliminary findings which included 14 ... not find any benefits as far as mood is concerned. ...
... in the recent issue of the American Journal of ... against a hip fracture. According to Dr. Susanne Hoidrup ... people undergo the aging process, regular physical activity should ... to control the alarming increase in hip fractures. ...
... are far more likely to miscarrry after IVF treatment- but ... say doctors. ,They are urging overweight women to change ... treatments. ,Obese women have long been known to have ... success rates for IVF do not match those of those ...
... Drug Administration (FDA) at a conference in Washington, approves the ... the sign of a protein known to cause cancer. It ... leukemia (CML). Other molecular-targeting drugs previously approved by ... but not with proteins that directly cause the disease. ...
... form of epidemic fevers, is spread by a virulent ... ,"We have 12 deaths (in the past fortnight) from ... in city hospitals, " Maharashtra state Health Minister Digvijay ... is being misdiagnosed by majority of the private doctors ...
... with the help of fertility treatment grow into emotionally ... ,The world's first study that followed in-vitro, or test ... youngsters who had been conceived through fertility treatments do ... ,Since Louise Brown, the world's first test tube ...
Cached Medicine News:
Set of 5 large bone curettes. One each of the following: angled small, straight small, angled medium, straight medium, and angled large....
Custom-made chisels....
Reduction Forceps with Points for precise reduction of bone fragments with minimal soft tissue contact....
Straight double action bone cutting rongeur....
Medicine Products: